Home Liver Diseases Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination

Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination

Credits to the Source Link Daniel
Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination
  • 1.

    Leoni, S. et al. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J. Gastroenterol. 24, 3361–3373 (2018).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 2.

    Karlas, T., Wiegand, J. & Berg, T. Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract. Res. Clin. Endocrinol. Metab. 27, 195–208 (2013).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 3.

    Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73–84 (2016).

    PubMed 
    Article 

    Google Scholar
     

  • 4.

    EASL, EASD & EASO. European Association For The Study Of The Liver (EASL) – European Association For The Study Of Diabetes (EASD) – European Association For The Study Of Obesity (EASO): Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59, 1121–1140 (2016).

  • 5.

    Hagström, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265–1273 (2017).

    PubMed 
    Article 

    Google Scholar
     

  • 6.

    Dulai, P. S. et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65, 1557–1565 (2017).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 7.

    Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397 (2015).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 8.

    Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 9.

    Sidhu, P. S. et al. EFSUMB guidelines on interventional ultrasound (INVUS), Part II—diagnostic ultrasound-guided interventional procedures (Long Version) TT – EFSUMB Leitlinien interventioneller Ultraschall (INVUS), Teil II – Diagnostische Ultraschall-gestützte Interventi. Ultraschall. Med. 36, E15–E35 (2015).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 10.

    Lorentzen, T. et al. EFSUMB guidelines on interventional ultrasound (INVUS), Part I. General aspects (long version). Ultraschall Med. 36, E1-14 (2015).

    MathSciNet 
    CAS 
    PubMed 

    Google Scholar
     

  • 11.

    Bedossa, P. & Carrat, F. Liver biopsy: The best, not the gold standard. J. Hepatol. 50, 1–3 (2009).

    PubMed 
    Article 

    Google Scholar
     

  • 12.

    Blond, E. et al. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: Do they lead to over-referral?. Diabetologia 60, 1218–1222 (2017).

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 13.

    European Association for Study of Liver & Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol. 63, 237–64 (2015).

  • 14.

    Dietrich, C. F. et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall der Medizin 38, e16–e47 (2017).


    Google Scholar
     

  • 15.

    Petta, S. et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment. Pharmacol. Ther. 46, 617–627 (2017).

    CAS 
    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 16.

    Eddowes, P. J. et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1717–1730 (2019).

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 17.

    Boursier, J. & Francque, S. Noninvasive tests of liver fibrosis and their combination in NAFLD: From selected patients to real-life populations. Hepatology 70, 1500–1502 (2019).

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 18.

    Roeb, E. et al. S2k Guideline non-alcoholic fatty liver disease. Z Gastroenterol. 53, 668–723 (2015).

    ADS 
    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 19.

    Petroff, D., Blüher, M. & Wiegand, J. Knowledge and practice regarding the German and the EASL-EASD-EASO NAFLD-guidelines among members of the German obesity society. Dig. Liver Dis. 50, 731–733 (2018).

    PubMed 
    Article 

    Google Scholar
     

  • 20.

    Rinella, M. E. et al. Practice patterns in NAFLD and NASH: Real life differs from published guidelines. Therap. Adv. Gastroenterol. 9, 4–12 (2016).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 21.

    Byrne, C. D. & Targher, G. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease: Is universal screening appropriate?. Diabetologia 59, 1141–1144 (2016).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 22.

    Newsome, P. N. et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study. Lancet Gastroenterol. Hepatol. 5, 362–373 (2020).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 23.

    Petersmann, A. et al. Definition, classification and diagnosis of diabetes mellitus. Exp. Clin. Endocrinol. Diabetes S01, S1–S7 (2019).


    Google Scholar
     

  • 24.

    Rydén, L. et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 34, 3035–3087 (2013).

    PubMed 
    Article 

    Google Scholar
     

  • 25.

    European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–402 (2016).

  • 26.

    European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes. Facts 9, 65–90 (2016).

  • 27.

    Karlas, T. et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS ONE 9, e91987 (2014).

    ADS 
    PubMed 
    PubMed Central 
    Article 
    CAS 

    Google Scholar
     

  • 28.

    Sasso, M. et al. Controlled attenuation parameter (CAP): A novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med. Biol. 36, 1825–1835 (2010).

    PubMed 
    Article 

    Google Scholar
     

  • 29.

    Karlas, T. et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J. Hepatol. 66, 1022–1030 (2017).

    PubMed 
    Article 

    Google Scholar
     

  • 30.

    McPherson, S. et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am. J. Gastroenterol. 112, 740–751 (2017).

    PubMed 
    Article 

    Google Scholar
     

  • 31.

    Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317–1325 (2006).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 32.

    Karlsen, T. H., Lammert, F. & Thompson, R. J. Genetics of liver disease: From pathophysiology to clinical practice. J. Hepatol. 62, S6–S14 (2015).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 33.

    Loomba, R. et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56, 943–951 (2012).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 34.

    Harman, D. J. et al. Obesity and type 2 diabetes are important risk factors underlying previously undiagnosed cirrhosis in general practice: A cross-sectional study using transient elastography. Aliment. Pharmacol. Ther. 47, 504–515 (2018).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 35.

    Karlas, T., Wiegand, J. & Petroff, D. Do NAFLD-patients require HCC screening?. Z. Gastroenterol. 57, 160–161 (2019).

    PubMed 
    Article 
    PubMed Central 

    Google Scholar
     

  • 36.

    Ratziu, V. et al. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J. Hepatol. 57, 376–383 (2012).

    PubMed 
    Article 

    Google Scholar
     

  • 37.

    Marjot, T. et al. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: Impact of a dedicated screening approach at a large university teaching hospital. Diabet. Med. 35, 89–98 (2018).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 38.

    Lai, L.-L. et al. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J. Gastroenterol. Hepatol. 34, 1396–1403 (2019).

    CAS 
    PubMed 

    Google Scholar
     

  • 39.

    Kwok, R. et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study. Gut 65, 1359–1368 (2016).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 40.

    Cherpitel, C. J. & Ye, Y. Validity of self-reports of drinking before injury by cause of injury and societal context among emergency department patients. Drug Alcohol Rev. 38, 523–529 (2019).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 41.

    Serra-Burriel, M. et al. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J. Hepatol. 71, 1141–1151 (2019).

    PubMed 
    Article 

    Google Scholar
     

  • 42.

    Mahady, S. E. et al. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. Clin. Gastroenterol. Hepatol. 15, 1453-1460.e1 (2017).

    PubMed 
    Article 

    Google Scholar
     

  • 43.

    Sberna, A. L. et al. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: Evaluation of their application in people with Type 2 diabetes. Diabet. Med. 35, 368–375 (2018).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 44.

    Bril, F. et al. Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes. Diabetes Care 43(2), 290–297 (2020).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 45.

    Kleiner, D. E. et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw. open 10, e1912565 (2019).

    Article 

    Google Scholar
     

  • 46.

    Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008).

    CAS 
    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 47.

    Krawczyk, M., Portincasa, P. & Lammert, F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin. Liver Dis. 33, 369–379 (2013).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 48.

    Basyte-Bacevice, V. et al. TM6SF2 and MBOAT7 gene variants in liver fibrosis and cirrhosis. Int. J. Mol. Sci. 20, 2 (2019).

    Article 
    CAS 

    Google Scholar
     

  • 49.

    Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554 (2015).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • 50.

    Thiagarajan, P. & Aithal, G. P. Drug development for nonalcoholic fatty liver disease: Landscape and challenges. J. Clin. Exp. Hepatol. 9, 515–521 (2019).

    PubMed 
    PubMed Central 
    Article 

    Google Scholar
     

  • 51.

    Mizuno, M. et al. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. Hepatol. Res. 47, 216–225 (2017).

    CAS 
    PubMed 
    Article 

    Google Scholar
     

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: